

Research Roundup

This month we discuss research exploring a diabetes drug for Parkinson's and share the latest funding announcement for two Parkinson's Fellowships. Read more for the latest research news and opportunities to get involved.

Research news

£600,000 awarded to support the next leaders of Parkinson's Research

Parkinson's UK has funded two future leaders in Parkinson's research who are pushing forward our understanding of the early stages and causes of Parkinson's.

New funding has been awarded to two researchers through our Fellowships programme: Dr Sophie Farrow at the University of Oxford and Dr Eduardo de Pablo-Fernandez at Queen Mary, University of London. The Fellowships will allow these researchers to devote their time to Parkinson's research, work towards establishing their own independent research groups and help nurture them as the next generation of leaders in Parkinson's research.

What are Sophie and Eduardo aiming to do?

Both researchers aim to add to our understanding of Parkinson's by looking at the causes of the condition and ways to detect the condition earlier.

Dr Sophie Farrow has been awarded £300,000 to explore how and why some changes in certain genes can increase a person's risk of Parkinson's. She will look at different types of brain cells and use existing samples from people with Parkinson's, such as blood samples and fluid from around someone's spinal cord, to try and build a better picture of how these genes are contributing to what goes wrong in Parkinson's.

Dr Sophie Farrow shares her aspirations for her research:

"My long-term goal is to use genetic approaches to provide insight into the origins of Parkinson's, to enable the development of preventative or curative treatments, as opposed to treating symptoms. I will integrate multiple genomic approaches to identify

1 April 2024

and prioritise potential drug targets, with the vision to accelerate early-stage drug target selection and repurposing for people with Parkinson's.

Dr Eduardo de Pablo-Fernandez has been awarded £299,237 to help find a way to detect Parkinson's earlier. He will do this by looking at people who experience symptoms related to sudden drops in blood pressure (pure autonomic failure) which can be an early sign of Parkinson's. He will follow a group of 100 people over 2 years to look at their symptoms and blood tests to see how many individuals go on to develop Parkinson's.

Dr Eduardo de Pablo-Fernandez shares his aspirations for his research:

"In addition to leading an exciting study on a neglected area of Parkinson's research, this fellowship represents an important step to become an established independent researcher. Results from this study will lay the foundation to create the first study in the UK to follow people with pure autonomic failure."

Diabetes drug shows potential to slow progression of movement symptoms

Lixisenatide, a diabetes drug being investigated for Parkinson's, shows potential to slow the progression of movement symptoms. Clinical trial results show that movement symptoms in people with Parkinson's receiving lixisenatide treatment did not deteriorate over a 12 month period, compared to those receiving a placebo where there was a slight worsening.

The results are from a study (LixiPark) of 156 people with Parkinson's who were less than 3 years into their diagnosis. 75 people received daily injections of lixisenatide, and 75 people an inactive (placebo) injection, over 12 months. This was conducted at multiple research sites across France and was supported by Cure Parkinson's and the Van Andel Institute through the International Linked Clinical Trials programme.

What is lixisenatide?

Lixisenatide is currently used in the treatment of type 2 diabetes. It works by targeting glucagon-like peptide-1 (GLP-1) receptors in the pancreas, which causes the release of a hormone called insulin and results in increased uptake of glucose (a form of sugar) by cells.

1 April 2024

It is being investigated for Parkinson's because GLP-1 receptors are also found in the brain, and lab-based experiments have suggested that activating them can boost the function of dopamine connections, have anti-inflammatory properties, improve energy production, and switch on cell survival signals. Lixisenatide is the second diabetes drug to go through clinical trials for Parkinson's. The other one being exenatide.

What do these results mean for people with Parkinson's?

Clinical trial results from both drugs show their potential to slow motor symptom progression. But, similarly to the results from the most recent exenatide trial, people taking lixisenatide didn't report any changes to their quality of life, or measurements of non-motor symptoms. This leaves unanswered questions about the potential of these drugs for people with Parkinson's. A phase 3 study of exenatide is underway to help answer some of these questions.

TOP HAT trial closes early - an update

The TOP HAT trial is closing early and we have an important update on next steps.

What is the TOP HAT trial?

This major trial funded through Parkinson's UK's Virtual Biotech programme set out to test a drug called ondansetron in people with Parkinson's or Lewy body dementia (LBD) who experience visual hallucinations.

Ondansetron is a drug that is already approved and in use in the UK, mainly to help reduce nausea in people undergoing cancer treatment. The drug first showed potential for treating visual hallucinations in Parkinson's in the early 1990s.

A nationwide study to test ondansetron for safety and effectiveness

Chief Investigator, Professor Suzanne Reeves from University College London, explains the aims of the TOP HAT trial:

"Up to 75% of people with Parkinson's may experience hallucinations at some point but current treatment options can cause side effects and increase mortality (risk of death).

"We desperately need better treatments to help people who experience hallucinations as part of their Parkinson's and small studies have suggested that ondansetron could have potential.

1 April 2024

"That's why we were keen to put it to the test in a large-scale study. More than 40 hospitals and clinics across the UK joined in the effort to achieve our goal of enrolling several hundred participants. We wanted to investigate whether ondansetron is better than a placebo at reducing the frequency and severity of visual hallucinations. Secondly, we wanted to understand whether ondansetron would be safe and well-tolerated in people with Parkinson's - this is always a vital question for any potential new treatment."

Why is the study closing early?

As in all clinical trials, an independent team, called the Data Monitoring and Ethics Committee (DMEC), was set up to monitor the trial. For TOP HAT they carefully monitored a wide range of things. These included known side effects of ondansetron on things such as heart rate and rhythm, constipation and headache. It also included other events such as falls, attendance at A&E, hospital admissions and deaths.

After the first 100 participants had taken part in the study a preliminary analysis was carried out to look at how well the study drug was tolerated and address any safety concerns as promptly as possible. After looking at this data, the DMEC recommended that recruitment to the TOP HAT trial should stop as there were more safety issues in those who received ondansetron than the placebo.

It is disappointing that the TOP HAT trial is stopping earlier than planned but any sign that a drug may be causing harm means the study must stop.

Next steps for the trial

All current participants have been asked to stop taking their study drugs (ondansetron or placebo) but will continue to be monitored to record any further safety issues as well as to assess their hallucinations.

In the coming months the TOP HAT team will finish collecting all the data from remaining participants in the study. They will then be able to conduct the final analysis. This will include looking in more detail at all the safety issues reported throughout the study as well as to see whether ondansetron had a beneficial effect on hallucinations. This will then inform whether ondansetron is still a viable option to be explored further for people with Parkinson's.

1 April 2024

Arthur Roach, Director of the Parkinson's Virtual Biotech at Parkinson's UK, comments:

"We are very grateful to every person who has taken part in this pioneering study. The results will give us vital information about the safety and effectiveness of ondansetron for people with Parkinson's. We will work with the TOP HAT team to share the full findings from this important study as soon as we can.

"If you or a loved one has participated in the study and you have further questions please contact the hospital team where you participated in the trial in the first instance."

Take part in research

Future planning: What is important to people with Parkinson's?

A PhD researcher at Oxford Brookes University aims to explore how people with Parkinson's and their health care professionals think about future planning. Future planning is a process where individuals who are at risk of being affected by memory or communication problems in the future discuss future priorities with their loved ones and health professionals.

Who do the researchers need?

- 150 people with Parkinson's

What is involved?

- Completing a 15 minute survey. This can be completed online, or by post. Request a postal version of the survey by contacting the researcher.
- For more information, please contact the researchers to be sent a copy of the participant information sheet

Interested in taking part?

Please contact Rachel Lee by email at 17028653@brookes.ac.uk or by calling 07891 655 100.

The deadline for taking part in this research is **1 August 2024**.